Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15
The DOI matches its Crossref record; 54 of the 55 references it cites were found in a registry or an index.
Abstract
An old cancer drug's degrading new look: Typically, cancer drugs that help only a small number of patients in clinical trials are not pursued. This might change in a future world of precision medicine, where biomarkers will match specific drugs to the patients most likely to respond. Han et al. identified the mechanism of action of a cancer drug called indisulam, a sulfonamide tested previously in patients with solid tumors. Indisulam and related sulfonamides killed cells by disrupting precursor mRNA splicing. The drugs targeted a specific RNA splicing factor for degradation by “gluing” it to the CUL4-DCAF15 ubiquitin ligase. Experiments with cancer cell lines suggest that future clinical trials of these drugs should focus on leukemias and lymphomas with high DCAF15 expression levels. Science , this issue p. eaal3755
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Similarly, aryl sulphonamides degrade the essential RNA-binding protein RBM39 by engaging DCAF15, the substrate receptor of the CRL4DCAF15 E3 ubiquitin ligase13–15.”
From The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K (2020) · cites this paper as [13]
In the citing paper
“it took two decades to determine that indisulam, and the related sulfonamides e7820 and chloroquinoxaline sulfonamide (cQS), were in fact glue degraders that targeted the splicing factor RBM39 (Han et al. 2017;uehara et al. 2017).”
From From serendipity to strategy: molecular glue degraders in cancer therapeutics (2025) · cites this paper as Han et al. 2017
In the citing paper
“indisulam facilitated an interaction between RBM39 and DcAF15, a substrate receptor component of the cRl4 DcAF15 ligase complex (Han et al. 2017;uehara et al. 2017).”
From From serendipity to strategy: molecular glue degraders in cancer therapeutics (2025) · cites this paper as Han et al. 2017
In the citing paper
“However, sulfonamides such as indisulam and similar SPlAMs were serendipitously discovered to degrade RBM39 by stabilizing its native interaction with cRl4 DcAF15 (Han et al. 2017; uehara et al. 2017) (Figure 4A).”
From From serendipity to strategy: molecular glue degraders in cancer therapeutics (2025) · cites this paper as Han et al. 2017
In the citing paper
“The same MG mechanism has subsequently been revealed for antitumor aryl-sulfonamides, which reprograms another CRL4 substrate receptor, DCAF15, to bind and degrade certain RNA-binding proteins21–26.”
From Defining molecular glues with a dual-nanobody cannabidiol sensor (2022) · cites this paper as [21]
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Fast gapped-read alignment with Bowtie 2
Langmead, B., & Salzberg, S. L. (2012) · Nature Methods · doi:10.1038/nmeth.1923 · Cited by 56,400
Kim, D., Pertea, G., Trapnell, C., Pimentel, H., Kelley, R., & Salzberg, S. L. (2013) · Genome Biology · doi:10.1186/gb-2013-14-4-r36 · Cited by 12,668 · cited 1×
“8) (52) to human reference genome (hg19) along with the gene annotation data downloaded from Illumina’s iGenomes (http://support.”
MethodMass Spectrometric Sequencing of Proteins from Silver-Stained Polyacrylamide Gels
Shevchenko, A., Wilm, M., Vorm, O., & Mann, M. (1996) · Analytical Chemistry · doi:10.1021/ac950914h · Cited by 8,995
Eng, J. K., McCormack, A. L., & Yates, J. R. (1994) · Journal of the American Society for Mass Spectrometry · doi:10.1016/1044-0305(94)80016-2 · Cited by 6,484 · cited 2×
“As peptides eluted they were subjected to electrospray ionization and then entered into an LTQ Orbitrap Velos Pro ion-trap mass spectrometer (Thermo Fisher Scientific, Waltham, MA).”
MethodNGS QC Toolkit: A Toolkit for Quality Control of Next Generation Sequencing Data
Patel, R. K., & Jain, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030619 · Cited by 2,917
Function and regulation of cullin–RING ubiquitin ligases
Petroski, M. D., & Deshaies, R. J. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1547 · Cited by 2,148
Identification of a Primary Target of Thalidomide Teratogenicity
Ito, T., Ando, H., Suzuki, T., Ogura, T., Hotta, K., Imamura, Y., Yamaguchi, Y., & Handa, H. (2010) · Science · doi:10.1126/science.1177319 · Cited by 2,136
An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer
Soucy, T. A., Smith, P. G., Milhollen, M. A., Berger, A. J., Gavin, J. M., Adhikari, S., Brownell, J. E., Burke, K. E., Cardin, D. P., Critchley, S., et al. (2009) · Nature · doi:10.1038/nature07884 · Cited by 1,990 · cited 7×
“In many cases, ubiquitin is added to substrates by cullinRING ligases (CRLs), which are multisubunit ubiquitin ligases (23).”
BackgroundInfluentialLenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
Krönke, J., Udeshi, N. D., Narla, A., Grauman, P., Hurst, S. N., McConkey, M., Svinkina, T., Heckl, D., Comer, E., Li, X., et al. (2014) · Science · doi:10.1126/science.1244851 · Cited by 1,879
Mechanism of auxin perception by the TIR1 ubiquitin ligase
Tan, X., Calderon-Villalobos, L. I. A., Sharon, M., Zheng, C., Robinson, C. V., Estelle, M., & Zheng, N. (2007) · Nature · doi:10.1038/nature05731 · Cited by 1,688 · cited 1×
“This is the same mechanism by which the plant hormone auxin acts like “molecular glue” to enhance an interaction between the E3 ubiquitin ligase receptor TIR1 and its substrates (43).”
Background
Cited by
Items 201–300 of 786
Proteolysis Targeting Chimeras (PROTACs): A Perspective on Integral Membrane Protein Degradation
Ruffilli, C., Röth, S., Rodrigo, M., Boyd, H., Zelcer, N., & Moreau, K. (2022) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.2c00142 · Cited by 53
Pre-mRNA splicing-associated diseases and therapies
Love, S. L., Emerson, J. D., Koide, K., & Hoskins, A. A. (2023) · RNA Biology · doi:10.1080/15476286.2023.2239601 · Cited by 54
Steering research on mRNA splicing in cancer towards clinical translation
Anczuków, O., Allain, F. H. ‐., Angarola, B. L., Black, D. L., Brooks, A. N., Cheng, C., Conesa, A., Crosse, E. I., Eyras, E., Guccione, E., et al. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00750-2 · Cited by 59
Potential of E3 Ubiquitin Ligases in Cancer Immunity: Opportunities and Challenges
Ye, P., Chi, X., Cha, J., Luo, S., Yang, G., Yan, X., & Yang, W. (2021) · Cells · doi:10.3390/cells10123309 · Cited by 54
Improved Proteomics-Based Drug Mechanism-of-Action Studies Using 16-Plex Isobaric Mass Tags
Zinn, N., Werner, T., Doce, C., Mathieson, T., Boecker, C., Sweetman, G., Fufezan, C., & Bantscheff, M. (2021) · Journal of Proteome Research · doi:10.1021/acs.jproteome.0c00900 · Cited by 49
Huang, H. H., Ferguson, I., Thornton, A. M., Bastola, P., Lam, C., Lin, Y.-H. T., Choudhry, P., Mariano, M. C., Marcoulis, M., Teo, C. F., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15521-4 · Cited by 51
Molecular glues to stabilise protein–protein interactions
Soini, L., Leysen, S., Davis, J., & Ottmann, C. (2022) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2022.102169 · Cited by 51
Routes to molecular glue degrader discovery
Liu, Y., Bai, J., Li, D., & Cang, Y. (2025) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2024.12.006 · Cited by 57
Vicente‐Blázquez, A., González, M., Álvarez, R., Mazo, S. D., Medarde, M., & Peláez, R. (2018) · Medicinal Research Reviews · doi:10.1002/med.21541 · Cited by 52
Bocchino, M., Zanotta, S., Capitelli, L., & Galati, D. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.664109 · Cited by 52
Potent hydrazone derivatives targeting esophageal cancer cells
Li, L., Peng, J., Zhou, W., Qiao, H., Deng, X., Li, Z.-H., Li, J.-D., Fu, Y.-D., Li, S., Sun, K., et al. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.02.033 · Cited by 48
DNA Methylation Patterning and the Regulation of Beta Cell Homeostasis
Parveen, N., & Dhawan, S. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.651258 · Cited by 50
RNA-binding proteins as therapeutic targets in cancer
Jungfleisch, J., & Gebauer, F. (2025) · RNA Biology · doi:10.1080/15476286.2025.2470511 · Cited by 51
Mboge, M. Y., Chen, Z., Wolff, A., Mathias, J. V., Tu, C., Brown, K. D., Bozdağ, M., Carta, F., Supuran, C. T., McKENNA, R. V., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0207417 · Cited by 47
RetractedAdmin, A., Weitz, J., Jacques-Silva, C., Qadir, M. M. F., Umland, O., Pereira, E., QURESHI, F., Tamayo, A., Dominguez-Bendala, J., Rodriguez‐Diaz, R., et al. (2020) · Diabetes · doi:10.2337/db19-0687 · Cited by 50
TK216 targets microtubules in Ewing sarcoma cells
Povedano, J. M., Li, V., Lake, K. E., Bai, X. L., Rallabandi, R., Kim, J., Xie, Y., Brabander, J. K. D., & McFadden, D. G. (2022) · Cell chemical biology · doi:10.1016/j.chembiol.2022.06.002 · Cited by 47
Self-citationEmerging strategies for prospective discovery of molecular glue degraders
Wang, B., Cao, S., & Zheng, N. (2024) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2024.102811 · Cited by 52
Alkylamine-tethered molecules recruit FBXO22 for targeted protein degradation
Kagiou, C., Cisneros, J. A., Farnung, J., Liwocha, J., Offensperger, F., Dong, K. D., Yang, K., Tin, G., Horstmann, C. S., Hinterndorfer, M., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-49739-3 · Cited by 53
Fabrication of Hydrogel Materials for Biomedical Applications
Yang, J., Olanrele, O. S., Zhang, X., & Hsu, C. C. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-0947-2_12 · Cited by 46
Systematic functional identification of cancer multi-drug resistance genes
Lau, M.-T., Ghazanfar, S., Parkin, A., Chou, A. S. Y., Rouaen, J. R. C., Littleboy, J. B., Nessem, D., Khuong, T. M., Névoltris, D., Schofield, P., et al. (2020) · Genome biology · doi:10.1186/s13059-020-1940-8 · Cited by 49
Small-Molecule Approaches to Targeted Protein Degradation
Faust, T. B., Donovan, K. A., Yue, H., Chamberlain, P. P., & Fischer, E. S. (2021) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-051420-114114 · Cited by 44
Pei, H., Guo, W., Peng, Y., Xiong, H., & Chen, Y. (2022) · Medicinal Research Reviews · doi:10.1002/med.21886 · Cited by 46
Advances and perspectives of proteolysis targeting chimeras (PROTACs) in drug discovery
Xi, J., Zhang, R., Chen, K., Yao, L., Li, M., Jiang, R., Li, X., & Fan, L. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.105848 · Cited by 47
Ye, Z., Zhang, X., Ma, W., & Zhang, F. (2023) · Green Chemistry · doi:10.1039/d3gc00175j · Cited by 44
New strategies to enhance the efficiency and precision of drug discovery
An, Q., Huang, L., Wang, C., Wang, D., & Tu, Y. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1550158 · Cited by 49
Wang, Y., Bao, Y., Zhang, S., & Wang, Z. (2020) · Science China Life Sciences · doi:10.1007/s11427-019-1605-0 · Cited by 47
Mechanical properties of cell- and microgel bead-laden oxidized alginate-gelatin hydrogels
Distler, T., Kretzschmar, L., Schneidereit, D., Girardo, S., Goswami, R., Friedrich, O., Detsch, R., Guck, J. R., Boccaccini, A. R., & Budday, S. (2021) · Biomaterials Science · doi:10.1039/d0bm02117b · Cited by 48
Selective autophagy as the basis of autophagy-based degraders
Takahashi, D., & Arimoto, H. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.05.006 · Cited by 46
Recent advances in targeted protein degraders as potential therapeutic agents
Yang, N., Kong, B., Zhu, Z., Huang, F., Zhang, L., Lu, T., Chen, Y., Zhang, Y., & Jiang, Y. (2023) · Molecular Diversity · doi:10.1007/s11030-023-10606-w · Cited by 45
Small-Molecule Degraders beyond PROTACs—Challenges and Opportunities
Kastl, J. M., Davies, G., Godsman, E., & Holdgate, G. A. (2021) · SLAS Discovery · doi:10.1177/2472555221991104 · Cited by 43
Kumar, S., Venkatachalapathy, M., Sistla, R. K., & Poongavanam, V. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.104205 · Cited by 50
Yang, Z., Hu, Q., Wang, L., Cao, J., Song, J., Song, L., & Zhang, Y. (2025) · Journal of Environmental Management · doi:10.1016/j.jenvman.2025.124668 · Cited by 46
Development of Cationic Quaternary Ammonium Sulfonamide Amino Lipids for Nucleic Acid Delivery
Miller, J. B., Kós, P., Tieu, V., Zhou, K., & Siegwart, D. J. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b15982 · Cited by 44
Small molecules that target the ubiquitin system
Wu, H. Q., Baker, D. A., & Ovaa, H. (2020) · Biochemical Society Transactions · doi:10.1042/bst20190535 · Cited by 47
Identification and selectivity profiling of small-molecule degraders via multi-omics approaches
Scholes, N. S., Mayor-Ruiz, C., & Winter, G. E. (2021) · Cell Chemical Biology · doi:10.1016/j.chembiol.2021.03.007 · Cited by 41
Tumor and local lymphoid tissue interaction determines prognosis in high-grade serous ovarian cancer
Lu, H., Lou, H., Wengert, G., Paudel, R., Patel, N. R., Desai, S., Crum, B., Linton‐Reid, K., Chen, M., Li, D., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101092 · Cited by 50
Bellail, A. C., Jin, H. R., Lo, H.-Y., Jung, S. H., Hamdouchi, C., Kim, D., Higgins, R. K., Blanck, M., le Sage, C., Cross, B. C. S., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abh1486 · Cited by 42
Rana, S., Mallareddy, J. R., Singh, S., Boghean, L., & Natarajan, A. (2021) · Cancers · doi:10.3390/cancers13215506 · Cited by 46
Setia, N., Almuqdadi, H. T. A., & Abid, M. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.116041 · Cited by 45
Substrate and Functional Diversity of Protein Lysine Post-translational Modifications
Hao, B., Chen, K., Zhai, L., Liu, M., Liu, B., & Tan, M. (2024) · Genomics Proteomics & Bioinformatics · doi:10.1093/gpbjnl/qzae019 · Cited by 47
Krasavin, M., Kalinin, S., Sharonova, T. V., & Supuran, C. T. (2020) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2020.1801674 · Cited by 41
E3-Specific Degrader Discovery by Dynamic Tracing of Substrate Receptor Abundance
Hanzl, A., Barone, E., Bauer, S., Yue, H., Nowak, R. P., Hahn, E., Pankevich, E. V., Koren, A., Kubicek, S., Fischer, E. S., et al. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.2c10784 · Cited by 41
Molecular basis of RNA-binding and autoregulation by the cancer-associated splicing factor RBM39
Campagne, S., Jutzi, D., Malard, F., Matoga, M., Romane, K., Feldmüller, M., Colombo, M., Ruepp, M., & Allain, F. H. ‐. (2023) · Nature Communications · doi:10.1038/s41467-023-40254-5 · Cited by 45
Sulfonamide Moiety as “Molecular Chimera” in the Design of New Drugs
Culletta, G., Tutone, M., Zappalà, M., & Almerico, A. M. (2022) · Current Medicinal Chemistry · doi:10.2174/0929867329666220729151500 · Cited by 40
Srivastava, R., Fernández-Ginés, R., Encinar, J. A., Cuadrado, A., & Wells, G. (2022) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2022.09.023 · Cited by 42
Biomarkers for RBM39 degradation in acute myeloid leukemia
Hsiehchen, D., Goralski, M., Kim, J., Xie, Y., & Nijhawan, D. (2020) · Leukemia · doi:10.1038/s41375-020-0729-9 · Cited by 39
Self-citationTargeted Protein Degradation: Current and Emerging Approaches for E3 Ligase Deconvolution
Xiao, Y., Yuan, Y., Liu, Y., Lin, Z., Zheng, G., Zhou, D., & Lv, D. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00723 · Cited by 42
Li, G., Henry, S. A., Liu, H., Kang, T., Nao, S.-C., Zhao, Y., Wu, C., Jin, J., Zhang, J., Leung, C., et al. (2020) · Chemical Science · doi:10.1039/c9sc05623h · Cited by 39
Targeted Protein Degradation Technology and Nanomedicine: Powerful Allies against Cancer
Lin, J., Liu, H., Wu, Y., Jin, J., Zhou, Y., Zhang, H., Nagle, D. G., Chen, H., Zhang, W., & Luan, X. (2023) · Small · doi:10.1002/smll.202207778 · Cited by 38
Applications of protein ubiquitylation and deubiquitylation in drug discovery
Chen, Y., Xue, H., & Jin, J. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.107264 · Cited by 43
Drug Discovery Approaches to Target E3 Ligases
Rodríguez-Gimeno, A., & Galdeano, C. (2024) · ChemBioChem · doi:10.1002/cbic.202400656 · Cited by 45
A microfluidic-induced C. elegans sleep state
Gonzales, D. L., Zhou, J., Fan, B., & Robinson, J. T. (2019) · Nature Communications · doi:10.1038/s41467-019-13008-5 · Cited by 40
Maneiro, M., Vita, E. D., Conole, D., Kounde, C. S., Zhang, Q., & Tate, E. W. (2021) · Progress in medicinal chemistry · doi:10.1016/bs.pmch.2021.01.002 · Cited by 41
Regulation of RNA Splicing: Aberrant Splicing Regulation and Therapeutic Targets in Cancer
Kitamura, K., & Nimura, K. (2021) · Cells · doi:10.3390/cells10040923 · Cited by 40
Prieto, C., Nguyen, D. T. T., Liu, Z., Wheat, J. C., Perez, A. R., Gourkanti, S., Chou, T., Barin, E., Velleca, A., Rohwetter, T. M., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00220-w · Cited by 49
Leveraging Chemotype-Specific Resistance for Drug Target Identification and Chemical Biology
Kapoor, T. M., & Miller, R. M. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.09.003 · Cited by 37
Diamonds in the Rough: Harnessing Tumor-Associated Myeloid Cells for Cancer Therapy
Clappaert, E. J., Murgaski, A., Damme, H. V., Kiss, M., & Laoui, D. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02250 · Cited by 41
Molecular glue degraders: exciting opportunities for novel drug discovery
Lemaitre, T., Cornu, M., Schwalen, F., Since, M., Kieffer, C., & Voisin-Chiret, A. S. (2024) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2024.2306845 · Cited by 36
Implications of frequent hitter E3 ligases in targeted protein degradation screens
Zhang, X., Simon, G. M., & Cravatt, B. F. (2025) · Nature Chemical Biology · doi:10.1038/s41589-024-01821-z · Cited by 37
Khaldan, A., Bouamrane, S., En-Nahli, F., El-Mernissi, R., Khatabi, K. E., Hmamouchi, R., Maghat, H., Ajana, M. A., Sbai, A., Bouachrıne, M., et al. (2021) · Heliyon · doi:10.1016/j.heliyon.2021.e06603 · Cited by 36
Designing a chemical inhibitor for the AAA protein spastin using active site mutations
Cupido, T., Pisa, R., Kelley, M. E., & Kapoor, T. M. (2019) · Nature Chemical Biology · doi:10.1038/s41589-019-0225-6 · Cited by 36
The splicing modulator sulfonamide indisulam reduces AR-V7 in prostate cancer cells
Melnyk, J. E., Steri, V., Nguyen, H. G., Hann, B. C., Feng, F. Y.-C., & Shokat, K. M. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2020.115712 · Cited by 47
Huang, W., Kew, C., Fernandes, S., Löhrke, A., Han, L. K., Demetriades, C., & Antebi, A. (2022) · Nature Aging · doi:10.1038/s43587-022-00275-z · Cited by 39
Ligand-induced genetic degradation as a tool for target validation
Yesbolatova, A., Tominari, Y., & Kanemaki, M. T. (2019) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2018.11.001 · Cited by 35
Ubiquitination and Ubiquitin-Like Modifications in Multiple Myeloma: Biology and Therapy
Wirth, M., Schick, M., Keller, U. B., & Krönke, J. (2020) · Cancers · doi:10.3390/cancers12123764 · Cited by 36
Key Considerations in Targeted Protein Degradation Drug Discovery and Development
Qin, L., Dai, H., & Wang, J. (2022) · Frontiers in Chemistry · doi:10.3389/fchem.2022.934337 · Cited by 37
Kim, S., Nowicki, K. W., Gross, B. A., & Wagner, W. R. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.121109 · Cited by 34
A comprehensive review of BET-targeting PROTACs for cancer therapy
Zhou, X., Zhao, F., Xu, Y.-T., Guan, Y., Yu, T., Zhang, Y., Duan, Y., & Zhao, Y. (2022) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2022.117033 · Cited by 40
Evaluation of Anticancer Activities of Novel Facile Synthesized Calix[n]arene Sulfonamide Analogs
Yılmaz, B., Bayraç, A. T., & Bayrakcı, M. (2019) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-019-03184-x · Cited by 34
Identification and characterization of cancer vulnerabilities via targeted protein degradation
Mayor-Ruiz, C., & Winter, G. E. (2019) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2018.12.003 · Cited by 33
Protein degraders - from thalidomide to new PROTACs
Ito, T. (2023) · The Journal of Biochemistry · doi:10.1093/jb/mvad113 · Cited by 36
Hygroscopic salt-modulated UiO-66: Synthesis and its open adsorption performance
Zhao, H., Zhang, Z., Hou, H., & Zhang, J. (2021) · Journal of Solid State Chemistry · doi:10.1016/j.jssc.2021.122304 · Cited by 34
Aberrant RNA splicing and therapeutic opportunities in cancers
Yamauchi, H., Nishimura, K., & Yoshimi, A. (2021) · Cancer Science · doi:10.1111/cas.15213 · Cited by 38
Alternative Splicing in Cancer and Immune Cells
Bernard, A., Boidot, R., & Végran, F. (2022) · Cancers · doi:10.3390/cancers14071726 · Cited by 35
Targeting the “undruggable”: RNA-binding proteins in the spotlight in cancer therapy
Mir, C., Garcia‐Mayea, Y., & LLeonart, M. E. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.06.008 · Cited by 33
Targeted protein degradation in CNS disorders: a promising route to novel therapeutics?
Kuemper, S., Cairns, A. G., Birchall, K., Yao, Z., & Large, J. M. (2024) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2024.1370509 · Cited by 35
FBXW7 Triggers Degradation of KMT2D to Favor Growth of Diffuse Large B-cell Lymphoma Cells
Saffie, R., Zhou, N., Rolland, D. C. M., Önder, Ö., Basrur, V., Campbell, S. L., Wellen, K. E., Elenitoba‐Johnson, K. S. J., Capell, B. C., & Busino, L. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-2247 · Cited by 33
Goncharov, A. O., Shender, V. О., Kuznetsova, K. G., Kliuchnikova, A. A., & Moshkovskii, S. A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23095240 · Cited by 34
FGFR redundancy limits the efficacy of FGFR4-selective inhibitors in hepatocellular carcinoma
Tao, Z., Cui, Y., Xu, X., & Han, T. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2208844119 · Cited by 38
Self-citationHallmarks of Splicing Defects in Cancer: Clinical Applications in the Era of Personalized Medicine
Rahman, M. A., Nasrin, F., Bhattacharjee, S., & Nandi, S. (2020) · Cancers · doi:10.3390/cancers12061381 · Cited by 33
Oligomeric Remodeling by Molecular Glues Revealed Using Native Mass Spectrometry and Mass Photometry
Huang, X., Kamadurai, H., Siuti, P., Ahmed, E., Bennett, J. L., & Donald, W. A. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.3c02655 · Cited by 31
Liang, X., Ren, H., Han, F., Liang, R., Zhao, J., & Liu, H. (2023) · Medicinal Research Reviews · doi:10.1002/med.21992 · Cited by 33
Ege, N., Bouguenina, H., Tatari, M. N., & Chopra, R. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.02.011 · Cited by 34
Molecular glues: enhanced protein-protein interactions and cell proteome editing
Weagel, E. G., Foulks, J. M., Siddiqui, A. Q., & Warner, S. L. (2022) · Medicinal Chemistry Research · doi:10.1007/s00044-022-02882-2 · Cited by 33
Progress of small molecules for targeted protein degradation: PROTACs and other technologies
Zhao, H., Xin, M., & Zhang, S. (2023) · Drug Development Research · doi:10.1002/ddr.22026 · Cited by 31
Targeting splicing factors for cancer therapy
Bashari, A., Siegfried, Z., & Karni, R. (2023) · RNA · doi:10.1261/rna.079585.123 · Cited by 35
Activity-based profiling of cullin–RING E3 networks by conformation-specific probes
Henneberg, L. T., Singh, J., Duda, D. M., Baek, K., Yanishevski, D., Murray, P. J., Mann, M., Sidhu, S. S., & Schulman, B. A. (2023) · Nature Chemical Biology · doi:10.1038/s41589-023-01392-5 · Cited by 36
Discovery of Molecular Glue Degraders via Isogenic Morphological Profiling
Ng, A., Offensperger, F., Cisneros, J. A., Scholes, N. S., Malik, M., Villanti, L., Rukavina, A., Ferrada, E., Hannich, J. T., Koren, A., et al. (2023) · ACS Chemical Biology · doi:10.1021/acschembio.3c00598 · Cited by 35
Unifying Catalysis Framework to Dissect Proteasomal Degradation Paradigms
Rodriguez-Rivera, F. P., & Levi, S. M. (2021) · ACS Central Science · doi:10.1021/acscentsci.1c00389 · Cited by 30
SuFEx-based chemical diversification for the systematic discovery of CRBN molecular glues
Carter, T. R., Milosevich, N., Dada, L., Shaum, J. B., Sharpless, K. B., Kitamura, S., & Erb, M. A. (2024) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2024.117699 · Cited by 33
Dynamic interactions drive early spliceosome assembly
Martínez‐Lumbreras, S., Morguet, C., & Sattler, M. (2024) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2024.102907 · Cited by 35
Zhuang, S., Li, F., Wang, L., Lai, Z., Li, D., Wu, H., Wu, J., Qu, J., Zhang, X., Zhang, M., et al. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-025-02145-8 · Cited by 32
Ammar, Y. A., El‐Sharief, A. M. S., Mohamed, Y. A., Mehany, A. B. M., & Ragab, A. (2018) · Al-Azhar Bulletin of Science · doi:10.21608/absb.2018.33767 · Cited by 30
Ubiquitinomics: History, methods, and applications in basic research and drug discovery
Steger, M., Karayel, Ö., & Demichev, V. (2022) · PROTEOMICS · doi:10.1002/pmic.202200074 · Cited by 32
Sette, C., & Paronetto, M. P. (2022) · Cancers · doi:10.3390/cancers14071827 · Cited by 36
Therapeutic Targeting of RNA Splicing in Cancer
Bonner, E. A., & Lee, S. C.-W. (2023) · Genes · doi:10.3390/genes14071378 · Cited by 33
Jablonowski, C. M., Quarni, W., Singh, S. V., Tan, H., Bostanthirige, D. H., Jin, H., Fang, J., Chang, T., Finkelstein, D., Cho, J., et al. (2024) · eLife · doi:10.7554/elife.90993 · Cited by 45
Targeting the E3 ubiquitin ligases DCAF15 and cereblon for cancer therapy
Nguyen, K. M., & Busino, L. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.03.007 · Cited by 30
Li, Q., & Kang, C. (2023) · FEBS Letters · doi:10.1002/1873-3468.14710 · Cited by 32
Expanding the ligand spaces for E3 ligases for the design of protein degraders
Saleem, R. S. Z., Schwalm, M. P., & Knapp, S. (2024) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2024.117718 · Cited by 36
Metadata
- Authors
- Han, T., Goralski, M., Gaskill, N., Capota, E., Kim, J., Ting, T. C., Xie, Y., Williams, N. S., & Nijhawan, D.
- Affiliations
- The University of Texas Southwestern Medical Center (US)
- Harold C. Simmons Comprehensive Cancer Center (US)
- Corresponding author
- Goralski, Maria
- Gaskill, Nicholas
- Nijhawan, Deepak
- ORCID
- Venue
- Science
- Published
- 2017-04-28
- Volume
- 356
- Issue
- 6336
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2596064219
- Cited by
- 762
- References
- 55
- Citations by year
- 2026: 72 · 2025: 86 · 2024: 122 · 2023: 99 · 2022: 86 · 2021: 99 · 2020: 86 · 2019: 56 · 2018: 40 · 2017: 15
- FWCI
- 22.22
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Welch Foundation (I-1879)
- Damon Runyon Cancer Research Foundation (CI-68-13)
- Cancer Prevention and Research Institute of Texas (RP150596)
- Life Sciences Research Foundation
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Research and Splicing
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Keywords
- indisulam, sulfonamides, RBM39, DCAF15, pre-mRNA splicing, splicing inhibition, proteasomal degradation, polyubiquitination, anticancer agents, drug resistance, biomarkers
- MeSH terms
- Animals, Antineoplastic Agents, Humans, Mutation, Neoplasms, Nuclear Proteins, RNA Splicing, Sulfonamides, RNA-Binding Proteins, Mice, Knockout, Drug Resistance, Neoplasm, Amino Acid Substitution, Xenograft Model Antitumor Assays, Ubiquitin-Protein Ligase Complexes, Cell Line, Tumor, Proteasome Endopeptidase Complex, Mice, Biomarkers, Pharmacological, Ubiquitination, Molecular Targeted Therapy, Proteolysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.